ClinicalTrials.gg
TerminatedNCT05048056Updated Feb 26, 2025

Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis

A Phase 2 interventional study of Placebo and AK120 in Atopic Dermatitis, sponsored by Akesobio Australia Pty Ltd. Terminated at 24 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-26.

Sponsored by Akesobio Australia Pty Ltd (part of Akeso) · Phase 2, Interventional, and Treatment

Why this study was terminated
Clinical study and development strategy adjustment

From the registry’s dates

  • Primary completion was May 2023, 3 years 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
79
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 639 studies in Dermatitis, Atopic with a site in United States — 78 open to participants now, 117 under way, 18 of them phase 3. Dermatitis, Atopic · United States.

Enrollment
296th of 544
79 · median 96
Started
2021
with 47 others
Phase 2
202 of 639
18 open now
Registered
434th of 639
by date

Among the 639 studies in Dermatitis, Atopic with a site in United States, this one is the 296th largest by enrollment of the 544 interventional ones that give a count, is one of 48 that started in 2021, is one of 202 in phase 2, and was the 434th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

78 of the 639 studies in Dermatitis, Atopic with a site in United States are open now. Recruiting first, the newest first:

73 more — sign in →

All 78 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 639 studies in Dermatitis, Atopic with a site in United States, or all of them as a file.
02

Study summary

This is a phase 2, multi-center, randomized, placebo-controlled, double-blind, parallel-group, dose-ranging study, conducted in subjects with moderate-to-severe atopic dermatitis.

Read the detailed description

This phase 2 study is designed to explore the efficacy and safety, as well as pharmacokinetics (PK), pharmacodynamics (PD) and immunogenicity of dose-ranging AK120 compared to placebo, which will generate information regarding the selection of dosing regimens with AK120 monotherapy treatment in adult subjects with moderate-to-severe AD.

Primary Objectives:

  • To evaluate the efficacy of AK120 in the treatment of adult subjects with moderate-to-severe Atopic Dermatitis (AD).

Secondary Objectives:

  • To evaluate the safety of AK120 in the treatment of adult subjects with moderate-to-severe AD.
  • To evaluate the Pharmacokinetics (PK), pharmacodynamics (PD) and immunogenicity of AK120 in adult subjects with moderate-to-severe AD.
03

Conditions studied

  • Atopic Dermatitis

Browse trials for

Keywords

  • Atopic Dermatitis
  • Monoclonal Antibodies
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Male or female, over the age of 18
  2. Chronic atopic dermatitis (AD) diagnosed at least 1 year.
  3. Subject with EASI score ≥16, IGA ≥ 3 (on the 0 to 4 IGA scale, in which 3 is moderate and 4 is severe), ≥ 10% body surface area (BSA) of AD involvement.
  4. Subjects with a history of an inadequate response or medically inappropriate use of topical drug treatment within 6 months.

Key Exclusion Criteria:

  1. Inadequate for prior drug therapy (eg. , / immunomodulating, biologics, phototherapy, Chinese traditional medicine, anti-infective agents).
  2. History of exposure to active TB, and/or history or current evidence of TB infection.
  3. Positive serology results at Screening for , or .
  4. Any history of vernal keratoconjunctivitis (VKC) or atopic keratoconjunctivitis (AKC) within 6 months before the baseline visit.
  5. History of clinical parasite infection, recent or planned travel to an area with endemic parasite infection within 6 months before the Screening visit
  6. Any medical or psychiatric condition, laboratory, or parameter which, in the opinion of the Investigator or the Sponsor's medical monitor, would place the subject at risk, interfere with participation in the study, or interfere with the interpretation of study results.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
79 participants (actual)

Study arms

  • Experimental
    AK120 Regimen 1

    AK120 Regimen 1- subcutaneous injection every 2 weeks for 30 weeks.

    Drug: AK120

  • Experimental
    AK120 Regimen 2

    AK120 Regimen 2- subcutaneous injection every 2 weeks for 30 weeks.

    Drug: AK120

  • Experimental
    Placebo to AK120

    Placebo subcutaneous injection every 2 weeks, then crossover to AK120 Regimen 1, subcutaneous injection at Week16, after primary endpoint evaluation

    Drug: Placebo · Drug: AK120

Interventions

  • DrugPlacebo

    Placebo subcutaneous injection every 2 weeks for 16 weeks then Crossover to AK120 Regimen 1

  • DrugAK120

    AK120 Regimen 1- subcutaneous injection every 2 weeks.

  • DrugAK120

    AK120 Regimen 2- subcutaneous injection every 2 weeks

06

What researchers measure

Primary outcomes

  1. Proportion of subjects achieving an Eczema Area and Severity Index (EASI) 75 response

    Time frame: At week 16

Secondary outcomes

  1. Proportion of subjects achieving the Investigator Global Assessment (IGA, on a 5-point scale) for clear (0) or almost clear (1)

    Time frame: At week 16

  2. Change in SCORing Atopic Dermatitis (SCORAD)

    Time frame: Baseline to Week 38

  3. Change in Pruritus-Numerical Rating Scale (P-NRS)

    Time frame: Baseline to Week 38

  4. Change in Body Surface Area (BSA) of AD involvement

    Time frame: Baseline to Week 38

  5. Change in Patient Oriented Eczema Measure (POEM)

    Time frame: Baseline to Week 38

  6. Individual subject AK120 concentrations in serum at different time points after AK120 administration

    Time frame: Baseline to Week 38

  7. Change in pharmacodynamics studies TARC/CCL17 and IgE

    Time frame: Baseline to week 24

  8. Anti-drug antibodies(ADAs)

    Time frame: Baseline to Week 38

  9. Adverse events(AEs)/serious adverse events(SAEs)

    Time frame: Baseline to Week 38

07

Study locations

24 sites
  • AkesoBio Investigative Site 2003
    Little Rock, Arkansas 72204, United States
  • AkesoBio Investigative Site 2010
    Canoga Park, California 91303, United States
  • AkesoBio Investigative Site 2021
    San Diego, California 92119, United States
  • AkesoBio Investigative Site 2023
    San Diego, California 92120, United States
  • AkesoBio Investigative Site 2017
    San Francisco, California 94127, United States
  • AkesoBio Investigative Site 2020
    Sherman Oaks, California 91043, United States
  • AkesoBio Investigative Site 2009
    Hialeah, Florida 33016, United States
  • AkesoBio Investigative Site 2001
    Hollywood, Florida 33021, United States
  • AkesoBio Investigative Site 2011
    Miami, Florida 33155, United States
  • AkesoBio Investigative Site 2002
    Weston, Florida 33331, United States
  • AkesoBio Investigative Site 2022
    Ridgeland, Mississippi 39157, United States
  • AkesoBio Investigative Site 2015
    Las Vegas, Nevada 89145, United States
  • AkesoBio Investigative Site 2013
    Spartanburg, South Carolina 29303, United States
  • AkesoBio Investigative Site 2005
    Rapid City, South Dakota 57702, United States
  • AkesoBio Investigative Site 2004
    Houston, Texas 77065, United States
  • AkesoBio Investigative Site 2018
    Houston, Texas 77074, United States
  • AkesoBio Investigative Site 3003
    Sydney, New South Wales 2145, Australia
  • AkesoBio Investigative Site 3002
    Woolloongabba, Queensland 4102, Australia
  • AkesoBio Investigative Site 3001
    Camberwell, Victoria 3145, Australia
  • AkesoBio Investigative Site 4003
    Auckland, 0626, New Zealand
  • AkesoBio Investigative Site 4001
    Auckland, 1010, New Zealand
  • AkesoBio Investigative Site 4005
    Christchurch, 8013, New Zealand
  • AkesoBio Investigative Site 4004
    Hamilton, 3204, New Zealand
  • AkesoBio Investigative Site 4004
    Wellington, 6242, New Zealand
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2021 to primary completion in May 2023, 19 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2021
First posted
Sep 17, 2021
StartActual
Sep 30, 2021
Primary completionActual
May 17, 2023
CompletionActual
May 17, 2023
Last update
Feb 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05048056
Responsible party
Sponsor
First posted
Sep 17, 2021
Start date
Sep 30, 2021
Primary completion
May 17, 2023
Completion
May 17, 2023
Last update
Feb 26, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AK120

Start the discussion